Macrocytosis due to treatment with sunitinib [10]

New England Journal of Medicine

Volumn 357, Issue 13, 2007, Pages 1351-1352

  Billemont, Bertrand ^a   Izzedine, Hassane ^a   Rixe, Olivier ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COBALAMIN; HEMOGLOBIN; IMATINIB; STEM CELL FACTOR; SUNITINIB;

ADULT; ANEMIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG TARGETING; FEMALE; GASTRITIS; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY CARCINOMA; LETTER; MALE; MEAN CORPUSCULAR VOLUME; MEGALOCYTOSIS; METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 34748914140     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc071867     Document Type: Letter

References (3)

1. Gillessen S, Graf L, Korte W, Cerny T. Macrocytosis and cobalamin deficiency in patients treated with sunitinib. N Engl J Med 2007;356:2330-1.
2. Aliberti S, Grignani G, Allione P, et al. Erythrocyte macrocytosis is a rather common, apparently uneventful yet unexplained finding in GIST imatinib (I) chronic therapy. J Clin Oncol 2005;23:Suppl:16S. abstract.
3. Khasawneh MF, Unnithan J, Choueiri T, et al. Macrocytosis in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKI's). J Clin Oncol 2007;25:Suppl:18S. abstract.